Shots:

• The approval is based on the P-III clinical trial program including Measure Up 1/2/AD Up that evaluates the efficacy & safety of Rinvoq (qd) as monothx. with TCS vs PBO in 2500+ adults & adolescents with AD
• In all three studies- the co-primary EPs showed 75% improvement in EASI 75 and vIGA-AD score of 0/1 (clear or almost clear) @16wks. The therapy demonstrated improvements in skin clearance and itch reduction
• Rinvoq is a JAK inhibitor that is used to treat adults and adolescents aged ≥12yrs. with AD who are not adequately controlled with a systemic treatment or when the use of the therapies is inadvisable

Ref: Abbvie | Image: abbvie